Welcome to Insider Healthcare. I’m Lydia Ramsey Pflanzer, and today in healthcare news:
- We got the pitch deck that kidney-care startup Strive Health used to raise $US140 ($181) million in its Series B;
- How DNA-testing companies are shaping the next chapter of the genetics industry;
- Moderna has started its vaccine trial in kids between 6 months and 12 years.
Alphabet’s VC arm just sank $US140 ($181) million into a startup that wants to unseat dialysis giants like DaVita. We got the pitch deck that convinced CapitalG to back Strive Health.
- Strive Health raised $US140 ($181) million in Series B funding on Tuesday. Alphabet’s CapitalG led the round.
- The startup works with insurers and health systems on a new way to care for people with mid- and late-stage kidney disease.
How 5 top DNA-testing companies like 23andMe and Color are shaping the next chapter of the genetics industry
- 23andMe in February said it’s going public in a deal that values the company at $US3.5 ($5) billion.
- Despite 23andMe’s success, the consumer genomics market has largely bottomed out, an analyst said.
- Others hoping to cash in on genetic health assessments have pivoted or shuttered efforts altogether.
- Moderna has begun testing its COVID-19 vaccine in children between 6 months and 12 years old.
- It plans to enroll 6,750 participants in the US and Canada in the trial.
- Getting children vaccinated is crucial to reaching herd immunity, according to Dr. Anthony Fauci.
More stories we’re reading today:
- The growing list of countries suspending use of the AstraZeneca vaccine may be doing much more harm than good, experts say (Insider)
- Grand Rounds is merging with Doctor on Demand in the latest digital health consolidation (CNBC)
- 65 of 100 of the largest hospitals in the US aren’t complying with the new price transparency rule (Modern Healthcare)
- Weddings could be safe this spring and summer, experts say – here’s how to go about it (Insider)